A team led by Scripps Research’s Peter Schultz developed T7-ORACLE, a synthetic biology platform leveraging an engineered T7 bacteriophage replisome to drive rapid, continuous, and precise protein evolution inside bacterial cells. This system accelerates mutation rates significantly without harming hosts, enabling protein variants with enhanced functions to be generated within days. This breakthrough facilitates advanced engineering of therapeutic proteins such as enzymes and antibodies, representing a leap forward in drug discovery and biotechnology development.